DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
CIFORADENANT
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity; Carcinoma, Non-Small-Cell Lung; Multiple Myeloma; Parkinson Disease
Adenosine A2a receptor antagonist
CIFORADENANT
×
Maximum Phase:
2
First Approval:
None
UNII:
8KFO2187CP
Molecule Type:
Small molecule
Molecular Formula:
C20H21N7O3
Molecular Weight:
407.43
AlogP:
2.12
PSA:
127.0
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ANTIMONY CATION (5+)
2
Small molecule
Investigational
Unknown
Unknown
Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous
Unknown
ANTIMONY CATION (5+)
×
Maximum Phase:
2
First Approval:
None
UNII:
841L03HG64
Molecule Type:
Small molecule
Molecular Formula:
Sb+5
Molecular Weight:
121.76
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
LADIRATUZUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Hemangiosarcoma
Tubulin inhibitor
LADIRATUZUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
VM4G5D1A60
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGCANTRATINIB
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Dermatitis, Atopic; Psoriasis
Nerve growth factor receptor Trk-A inhibitor
PEGCANTRATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
VG44NU1168
Molecule Type:
Small molecule
Molecular Formula:
C30H24N4O6
Molecular Weight:
536.54
AlogP:
4.12
PSA:
104.03
HBD:
1.0
HBA:
#RotB:
3.0
Source:
.ALPHA.-R-LIPOIC ACID CHOLINE ESTER
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
.ALPHA.-R-LIPOIC ACID CHOLINE ESTER
×
Maximum Phase:
2
First Approval:
None
UNII:
H3PX4O36U1
Molecule Type:
Small molecule
Molecular Formula:
C13H26NO2S2+
Molecular Weight:
292.49
AlogP:
2.95
PSA:
26.3
HBD:
0.0
HBA:
#RotB:
8.0
Source:
XL-820
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Gastrointestinal Stromal Tumors
Platelet-derived growth factor receptor inhibitor
XL-820
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RIMACALIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Unknown
RIMACALIB
×
Maximum Phase:
2
First Approval:
None
UNII:
BZ76J3N815
Molecule Type:
Small molecule
Molecular Formula:
C22H23FN4O2
Molecular Weight:
394.45
AlogP:
4.31
PSA:
74.38
HBD:
2.0
HBA:
#RotB:
4.0
Source:
VEDROPREVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C, Chronic
Hepatitis C virus serine protease, NS3/NS4A inhibitor
VEDROPREVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
KGD958X2B9
Molecule Type:
Small molecule
Molecular Formula:
C45H60ClN7O9S
Molecular Weight:
910.53
AlogP:
6.2
PSA:
193.78
HBD:
4.0
HBA:
#RotB:
16.0
Source:
VOPRATELIMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms
Inducible T-cell costimulator agonist
VOPRATELIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
QXN20J93AH
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMDOXOVIR
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
AMDOXOVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
54I81H0M9C
Molecule Type:
Small molecule
Molecular Formula:
C9H12N6O3
Molecular Weight:
252.23
AlogP:
-1.15
PSA:
134.33
HBD:
3.0
HBA:
#RotB:
2.0
Source:
OLINCIGUAT
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell; Esophageal Achalasia
Soluble guanylate cyclase positive allosteric modulator
OLINCIGUAT
×
Maximum Phase:
2
First Approval:
None
UNII:
PD5F4ZXD21
Molecule Type:
Small molecule
Molecular Formula:
C21H16F5N7O3
Molecular Weight:
509.4
AlogP:
2.51
PSA:
144.98
HBD:
3.0
HBA:
#RotB:
8.0
Source:
ANRUKINZUMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma; Colitis, Ulcerative
Interleukin-13 inhibitor
ANRUKINZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
OU46IGC49F
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ODRONEXTAMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Follicular
B-lymphocyte antigen CD20 binding agent
ODRONEXTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
8R5CM46UIO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZD-6126
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Renal Cell; Colorectal Neoplasms; Neoplasm Metastasis
Unknown
ZD-6126
×
Maximum Phase:
2
First Approval:
None
UNII:
GBO3S6M9W7
Molecule Type:
Small molecule
Molecular Formula:
C20H24NO8P
Molecular Weight:
437.39
AlogP:
2.97
PSA:
123.55
HBD:
3.0
HBA:
#RotB:
6.0
Source:
GOZETOTIDE ALF-18
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Neoplasms
Unknown
GOZETOTIDE ALF-18
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C44H60AlFN6O17
Molecular Weight:
989.97
AlogP:
1.55
PSA:
370.07
HBD:
12.0
HBA:
#RotB:
35.0
Source:
PENTALYTE
2
Small molecule
Investigational
Unknown
Unknown
Nasopharyngeal Neoplasms
Unknown
PENTALYTE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
H3Cl2K2MgNa3O12P2S
Molecular Weight:
531.4
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
RISUTEGANIB
2
Protein
Investigational
Unknown
Unknown
Macular Degeneration
Unknown
RISUTEGANIB
×
Maximum Phase:
2
First Approval:
None
UNII:
123DNA66IA
Molecule Type:
Protein
Molecular Formula:
C22H39N9O11S
Molecular Weight:
637.67
AlogP:
-5.88
PSA:
336.53
HBD:
11.0
HBA:
#RotB:
17.0
Source:
CENTANAFADINE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Unknown
CENTANAFADINE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
265DN9X85W
Molecule Type:
Small molecule
Molecular Formula:
C15H16ClN
Molecular Weight:
245.75
AlogP:
2.7
PSA:
12.03
HBD:
1.0
HBA:
#RotB:
1.0
Source:
MVA85A
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MVA85A
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DILPACIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
DILPACIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
F27LAH6D5O
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALT-2074
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ALT-2074
×
Maximum Phase:
2
First Approval:
None
UNII:
634U7OUR4R
Molecule Type:
Small molecule
Molecular Formula:
C10H13NSe
Molecular Weight:
226.18
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GELDANAMYCIN
2
Small molecule
Investigational
Unknown
Unknown
Kidney Neoplasms; von Hippel-Lindau Disease
Unknown
GELDANAMYCIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Z3K3VJ16KU
Molecule Type:
Small molecule
Molecular Formula:
C29H40N2O9
Molecular Weight:
560.64
AlogP:
2.41
PSA:
163.48
HBD:
3.0
HBA:
#RotB:
4.0
Source:
UPROSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms; Leukemia, Myeloid, Acute; Melanoma; Multiple Myeloma; Uterine Cervical Neoplasms
Serine/threonine-protein kinase AKT inhibitor
UPROSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
ZXM835LQ5E
Molecule Type:
Small molecule
Molecular Formula:
C18H16Cl2F2N4O2
Molecular Weight:
429.25
AlogP:
3.56
PSA:
86.08
HBD:
2.0
HBA:
#RotB:
6.0
Source:
ILEPATRIL
2
Small molecule
Investigational
Unknown
Unknown
Hypertension
Angiotensin-converting enzyme inhibitor
ILEPATRIL
×
Maximum Phase:
2
First Approval:
None
UNII:
5N1YAP5FCM
Molecule Type:
Small molecule
Molecular Formula:
C22H28N2O5S
Molecular Weight:
432.54
AlogP:
2.54
PSA:
103.78
HBD:
2.0
HBA:
#RotB:
5.0
Source:
ONALESPIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms, Castration-Resistant
Heat shock protein HSP90 inhibitor
ONALESPIB
×
Maximum Phase:
2
First Approval:
None
UNII:
Q7Y33N57ZZ
Molecule Type:
Small molecule
Molecular Formula:
C24H31N3O3
Molecular Weight:
409.53
AlogP:
3.12
PSA:
67.25
HBD:
2.0
HBA:
#RotB:
4.0
Source:
OCR-002
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
OCR-002
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVE8134
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Peroxisome proliferator-activated receptor alpha agonist
AVE8134
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SELATOGREL
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Coronary Disease; Myocardial Infarction
Purinergic receptor P2Y12 antagonist
SELATOGREL
×
Maximum Phase:
2
First Approval:
None
UNII:
6DPK7O4PR7
Molecule Type:
Small molecule
Molecular Formula:
C28H39N6O8P
Molecular Weight:
618.63
AlogP:
1.73
PSA:
174.73
HBD:
3.0
HBA:
#RotB:
11.0
Source:
MAPATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Multiple Myeloma
TRAIL receptor-1 agonist
MAPATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
WZ1025JPGR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MAVOGLURANT
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Alcohol Drinking; Gastroesophageal Reflux; Kidney Diseases; Liver Diseases; Chorea; Cocaine-Related Disorders; Fragile X Syndrome; Huntington Disease; Obsessive-Compulsive Disorder; Parkinson Disease
Metabotropic glutamate receptor 5 antagonist
MAVOGLURANT
×
Maximum Phase:
2
First Approval:
None
UNII:
GT0I9SV4F6
Molecule Type:
Small molecule
Molecular Formula:
C19H23NO3
Molecular Weight:
313.4
AlogP:
2.72
PSA:
49.77
HBD:
1.0
HBA:
#RotB:
0.0
Source:
TRIFOLIUM PRATENSE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
TRIFOLIUM PRATENSE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FORETINIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Lung Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Neoplasms
Hepatocyte growth factor receptor inhibitor
FORETINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
81FH7VK1C4
Molecule Type:
Small molecule
Molecular Formula:
C34H34F2N4O6
Molecular Weight:
632.66
AlogP:
5.77
PSA:
111.25
HBD:
2.0
HBA:
#RotB:
12.0
Source:
ANTHRAX VACCINE ABSORBED
2
Unknown
Investigational
Unknown
Unknown
Anthrax
Unknown
ANTHRAX VACCINE ABSORBED
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RAMATROBAN
2
Small molecule
Investigational
Unknown
Unknown
Asthma
G protein-coupled receptor 44 antagonist
RAMATROBAN
×
Maximum Phase:
2
First Approval:
None
UNII:
P1ALI72U6C
Molecule Type:
Small molecule
Molecular Formula:
C21H21FN2O4S
Molecular Weight:
416.47
AlogP:
3.09
PSA:
88.4
HBD:
2.0
HBA:
#RotB:
6.0
Source:
SGS-742
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
GABA-B receptor antagonist
SGS-742
×
Maximum Phase:
2
First Approval:
None
UNII:
GBZ5UC0RME
Molecule Type:
Small molecule
Molecular Formula:
C7H18NO2P
Molecular Weight:
179.2
AlogP:
1.41
PSA:
63.32
HBD:
2.0
HBA:
#RotB:
6.0
Source:
1
2
…
160
161
162
163
164
165
166
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA